Initial serum tumor marker change predicts progression-free and overall survival in immune checkpoint blockade treated non-small cell lung cancer

被引：0
|
作者：
Lang, David [1 ]
Horner, Andreas [1 ]
Brehm, Elmar [1 ]
Romain, Silas [2 ]
Kaiser, Bernhard [1 ]
Lamprecht, Bernd [1 ]
机构：
[1] Kepler Univ Hosp, Dept Pulmonol, Linz, Austria
[2] Johannes Kepler Univ Linz, Fac Med, Linz, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2018年 / 130卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P44
引用
收藏
页码：618 / 619
页数：2
相关论文
共 50 条
  • [31] Oncogene Mutations in Non-Small Cell Lung Cancer Have Increased Progression Free Survival and Overall Survival
    Dudzinski, S.
    Chen, H.
    Cameron, B.
    Li, B.
    Chambless, L. B.
    Luo, G.
    Morales-Paliza, M.
    Thompson, R.
    Horn, L.
    York, S.
    Lovly, C. M.
    Cmelak, A.
    Kirschner, A. N.
    Attia, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E114 - E115
  • [32] Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors
    Liu, Zhenzhen
    Diao, Yuzhu
    Li, Xiaoling
    BMC CANCER, 2022, 22 (01)
  • [33] Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors
    Zhenzhen Liu
    Yuzhu Diao
    Xiaoling Li
    BMC Cancer, 22
  • [34] Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy
    Mark Uhlenbruch
    Stefan Krüger
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2079 - 2082
  • [35] Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
    Azuma, Koichi
    Komatsu, Nobukazu
    Hattori, Satoshi
    Matsueda, Satoko
    Kawahara, Akihiko
    Sasada, Tetsuro
    Itoh, Kyogo
    Hoshino, Tomoaki
    PLOS ONE, 2014, 9 (01):
  • [36] Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy
    Bhatt, P.
    Bonomi, P.
    Basu, S.
    Batus, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S868 - S869
  • [37] Prognostic Model for Progression-Free Survival in Patients With Stage III Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation
    Peulen, H. M.
    Uyterlinde, W.
    Belderbos, J.
    Vincent, A.
    Korse, C.
    van Diessen, J.
    Sonke, J. J.
    van den Heuvel, M. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S657 - S657
  • [38] Impact of PTVon progression-free survival in inoperable stage III non-small cell lung cancer patients treated with chemoradioimmunotherapy
    Taugner, J.
    Karin, M.
    Kaesmann, L.
    Eze, C.
    Floersch, B.
    Guggenberger, J.
    Tufman, A.
    Belka, C.
    Manapov, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S741 - S742
  • [39] Individual-level data on the relationships of progression-free survival, post-progression survival and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer
    Imai, H.
    Takahashi, T.
    Mori, K.
    Ono, A.
    Akamatsu, H.
    Shukuya, T.
    Taira, T.
    Kenmotsu, H.
    Naito, T.
    Murakami, H.
    Endo, M.
    Nakajima, T.
    Yamamoto, N.
    NEOPLASMA, 2014, 61 (02) : 233 - 240
  • [40] CNS Metastasis Negatively Impact Overall Survival of Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors
    Souza, C.
    Spina Donadio, M. D.
    Simoes, M. F.
    Maciel Santana, D.
    Barbosa De Medeiros, M. F.
    Mendes Gomes, L. B.
    Petrocchi Corassa, M.
    De Freitas, H.
    De Lima, V. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S289 - S289
12345